Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C119665
http://purl.obolibrary.org/obo/NCIT_C119665
|
|---|---|
| Preferred Name | Gilteritinib Fumarate |
| Definitions |
The fumarate salt form of gilteritinib, an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | The fumarate salt form of gilteritinib, an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival. |
|---|---|
| prefLabel | Gilteritinib Fumarate
|
| label | Gilteritinib Fumarate
|
| PDQ_Closed_Trial_Search_ID | 792549
|
| code | C119665
|
| Has_Target | |
| prefixIRI | NCIT:C119665
|
| in_subset |
See more
See less
|
| Display_Name | Gilteritinib Fumarate
|
| Preferred_Name | Gilteritinib Fumarate
|
| FDA_UNII_Code | 5RZZ0Z1GJT
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Gilteritinib Fumarate
|
| CAS_Registry | 1254053-84-3
|
| NCI_Drug_Dictionary_ID | 792549
|
| Has_Free_Acid_Or_Base_Form | |
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 792549
|
| Accepted_Therapeutic_Use_For | adults with acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation when the disease has come back or has not improved after previous treatment(s).
relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C3896946
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |